Jim Cramer Highlights Baker Hughes' $13.6 Billion LNG Move
'We might as well have a booming natural gas industry, one that gives our country a lot more geopolitical clout, especially when some of our trading enemies are still heavily into the dirtiest fossil fuel, coal. We're already seeing the benefits. This morning, Baker Hughes, the oil service company, paid $13.6 billion for Chart Industries, a company with expertise in building out these LNG facilities. It won't be the only deal there, believe me. So whether you love deregulation or hate it, you should try to take advantage of it for your portfolio. Right now, there's a lot to take advantage of, including anything LNG.'
A drilling rig on a remote oilfield, its tower silhouetted against a setting sunset.
Baker Hughes (NASDAQ:BKR) delivers technologies and services for oilfield operations, drilling, and subsea systems, including exploration and production support. Moreover, the company provides energy and industrial equipment, monitoring solutions, and carbon-related technologies.
While we acknowledge the potential of BKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 minutes ago
- CNBC
Here are 3 stocks that are working in Thursday's mixed market and another that is not
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Thursday's key moments. 1. Tech stocks rose Thursday on the broad exemptions included in the chip tariffs that President Donald Trump announced after Wednesday's close. Club name Nvidia jumped 2%. Shares of Apple , also in the portfolio, rallied for a second day after unveiling a new $100 billion investment in U.S. manufacturing. Thursday did mark the beginning of so-called reciprocal tariffs for countries without trade deals. The tech-heavy Nasdaq was the big winner so far, while the S & P 500 was on either side of unchanged. 2. Club stock Eli Lilly was having a terrible day after the drugmaker's late-stage trial data on its obesity pill did not show the kind of weight loss that investors had anticipated. The data overshadowed what was an excellent quarter and a full-year guidance boost. Nevertheless, Jim Cramer said that CEO Dave Ricks' tone on the trial data during the conference call also didn't do the stock any favors. We're still debating what to do next with the stock. We did sell some shares of Lilly last week after GLP-1 competitor Novo Nordisk 's quarter disappointed. Our full analysis of the Lilly situation will be sent out later Thursday. Check your inboxes and texts. 3. Costco stock rose modestly after another good month of sales. It also benefited from the general upswing in retail given the expectation that the Federal Reserve will lower interest rates at next month's meeting. After Wednesday's close, Costco said U.S. same-store sales, called comps in the industry, accelerated to 6.5%, when excluding gas sales and currency fluctuations. Jim said he sees Costco stock working its way back to the all-time highs since back in February. 4. Stocks covered in Thursday's rapid fire at the end of the video were e.l.f. Beauty , Dutch Bros , DoorDash , Airbnb , and Fortinet . (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
29 minutes ago
- Yahoo
BlinkRx Launches "Operation Access Now" to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs
Operation Access Now enables pharmaceutical manufacturers to launch direct‑to‑patient programs within 21 days NEW YORK, August 07, 2025--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional access models struggle to meet patient and provider expectations, leading brands are turning to faster, more scalable approaches. BlinkRx's national infrastructure already supports millions of patients across all 50 states. The platform's patient-centric design removes every barrier for patients to start and stay on therapy and delivers significant lift for brands: on average, 52% more patient starts and 41% more fills per patient. With Operation Access Now, the initiative enables: Rapid Stand‑Up: DTP programs that can be operational in as little as 21 days, thanks to BlinkRx's turnkey platform and flexible rules engine. Future-Proof: A modular platform that allows pharmaceutical manufacturers to start with a DTP solution and expand into future capabilities as needs and regulations change. For example, the platform can be deployed for DTB models, and can service both cashpay and insurance patients. Scale: Unique automation capabilities that enable pharmaceutical manufacturers to effortlessly scale based on patient demand and adoption. Legacy DTP solutions, such as copay cards and standalone cash pharmacies, are often costly, inefficient, and prone to patient and physician frustration- causing delays in access, misuse, and poor experiences. BlinkRx's platform addresses these ecosystem issues while ensuring strict regulatory compliance. "Operation Access Now is about removing every barrier between manufacturers and the patients who need their therapies," said Geoffrey Chaiken, Co‑Founder and CEO of BlinkRx. "We're prepared to enable manufacturers to deploy DTP programs and deliver the speed, scale, and flexibility the market demands." About BlinkRx BlinkRx is a Prescription Lifecycle Management Platform that allows the most innovative Life Sciences companies to design every aspect of the prescription journey to unlock branded medication affordability and access for all Americans. Learn more at View source version on Contacts For media inquiries, please contact: Press@
Yahoo
29 minutes ago
- Yahoo
Crocs Sinks Most Since March 2020 on Tariffs, Cautious Consumers
(Bloomberg) -- Crocs Inc. shares dropped the most since the start of the Covid-19 pandemic on a weaker outlook, with the maker of colorful clogs warning that cautious consumers are further pulling back on spending. All Hail the Humble Speed Hump Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Three Deaths Reported as NYC Legionnaires' Outbreak Spreads Major Istanbul Projects Are Stalling as City Leaders Sit in Jail PATH Train Service Resumes After Fire at Jersey City Station Third-quarter revenue will decline approximately 9% to 11%, the company said on Thursday, well below analysts' average estimate for a gain of less than 1%. On Crocs' earnings call with analysts, executives said they won't reinstate full-year guidance, which it first withdrew earlier this year, due to changing global trade policies. The stock fell as much as 29% in Thursday trading in New York, the most since March 2020. The drop pushed the shares' year-to-date decline to nearly 30%, versus a 7.7% increase for the Russell 3000 Index. Chief Executive Officer Andrew Rees said US consumers, faced with price increases, are behaving 'cautiously around discretionary spending.' This 'has the potential to be a further drag on an already choiceful consumer,' he added. 'They're not even going to the stores and we see traffic down,' he said, adding the current conditions are preventing the company from raising prices to compensate for the impact of tariffs on countries where Crocs produces footwear. Crocs joins companies such as Steve Madden Ltd. and Lululemon Athletica Inc. that have been hit simultaneously by economic uncertainty and higher tariffs on nations such as China, which produces a large volume of apparel and footwear. In the three months ended March 31, Crocs reported that China produced around 22% of products send to the US — a percentage the company plans to reduce. A 'predominant portion' of merchandise also comes from Vietnam, Indonesia, India and Cambodia. Crocs is focusing on managing its expenses through cost cuts, inventory reduction and fewer promotions. 'Crocs might have a tougher time navigating tariff pressures, given its decision to pull back on promotions to preserve brand image,' Bloomberg Intelligence analyst Abigail Gilmartin said in a note. --With assistance from Katerina Petroff and Micah Barkley. (Updates with conference call detail and shares trading.) The Pizza Oven Startup With a Plan to Own Every Piece of the Pie Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay A High-Rise Push Is Helping Mumbai Squeeze in Pools, Gyms and Greenery Government Steps Up Campaign Against Business School Diversity ©2025 Bloomberg L.P. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
